NBIX
Neurocrine Biosciences, Inc.Healthcare · $14.3B market cap
Verdict
Share price
$143.18
close of Oct 3, 2026
Fair value
$51.19
Sticker Price
Payback Price
$20.48
buy price
NBIX is Overpriced: at $143.18 it trades 180% above its fair value of $51.19. Its buy price (Payback Price) is $20.48, 86% below today's price. Business quality is strong: all 5 key numbers clear the 10% bar.
How we valued it
Justified P/B (Financials). It has earned a steady return on its equity for years, and its tangible assets are worth 23% of its share price. For a business like that, book value and the return on it are a sturdier guide than an earnings forecast.
Business quality
5 of 5 clear the 10% bar. What are the Big Five?
Follow NBIX
Get notified when it reaches its buy price of $20.48. Free.
Create a free accountSuperinvestors
1 of the investors we track holds NBIX. Who we track
Insider activity
Since Jun 26, 2026: no open-market purchases, 10 sales worth $7.5M and 12 other filings (stock awards, tax withholding and similar). Why purchases matter
Sales
BENEVICH ERIC
Chief Commercial Officer · 2026-09-09
Sold
$333K
Norwalk Leslie V
director · 2026-07-28
Sold
$228K
Delaet Ingrid
Chief Regulatory Officer · 2026-07-10
Sold
$791K
Delaet Ingrid
Chief Regulatory Officer · 2026-07-09
Sold
$1.5M
Lippoldt Darin
Chief Legal Officer · 2026-07-09
Sold
$1.8M
Show all 10 salesShow fewer
Delaet Ingrid
Chief Regulatory Officer · 2026-07-08
Sold
$489K
Delaet Ingrid
Chief Regulatory Officer · 2026-07-07
Sold
$607K
Lippoldt Darin
Chief Legal Officer · 2026-06-29
Sold
$289K
Lippoldt Darin
Chief Legal Officer · 2026-06-29
Sold
$1.4M
Lippoldt Darin
Chief Legal Officer · 2026-06-26
Sold
$34K
Other filings
BENEVICH ERIC
Chief Commercial Officer · 2026-09-09
Option exercise
$138K
SHERWIN STEPHEN A
director · 2026-09-02
G-Gift
1,000 shares
Onyia Jude
Chief Scientific Officer · 2026-08-04
G-Gift
2,409 shares
Norwalk Leslie V
director · 2026-07-29
Option exercise
$117K
Delaet Ingrid
Chief Regulatory Officer · 2026-07-10
Option exercise
$463K
Show all 12 other filingsShow fewer
Delaet Ingrid
Chief Regulatory Officer · 2026-07-09
Option exercise
$873K
Lippoldt Darin
Chief Legal Officer · 2026-07-09
Option exercise
$815K
Delaet Ingrid
Chief Regulatory Officer · 2026-07-08
Option exercise
$283K
Delaet Ingrid
Chief Regulatory Officer · 2026-07-07
Option exercise
$352K
Lippoldt Darin
Chief Legal Officer · 2026-06-29
Option exercise
$138K
Lippoldt Darin
Chief Legal Officer · 2026-06-29
Option exercise
$661K
Lippoldt Darin
Chief Legal Officer · 2026-06-26
Option exercise
$16K
About Neurocrine Biosciences, Inc.
Neurocrine Biosciences, Inc. is a pharmaceutical firm dedicated to the creation, advancement, and commercialization of medicines addressing a spectrum of neurological, endocrine, and psychiatric conditions. Its current therapeutic pipeline and marketed products target disorders such as tardive dyskinesia, Parkinson's disease, endometriosis, and uterine fibroids, alongside numerous experimental compounds in various…
Biotechnology
Fair value and Payback Price are estimates from the company's reported financials, not investment advice. Prices as of the close of Oct 3, 2026. How the Payback Price works